We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





First of Its Kind Product Receives CE-Marking for Respiratory Infection Detection Using Smart Wearable Technology

By HospiMedica International staff writers
Posted on 10 Mar 2021
A first of its kind product has received CE-marking for the detection of respiratory infection, including COVID-19, using smart wearable technology.

Empatica (Boston, MA, USA) has been awarded CE-certification for its Aura system to detect and alert to respiratory infections, including COVID-19, early and before visible symptoms appear. More...
Empatica has received its CE mark as a Class lla medical device, meaning that Aura, as well as its remote health monitoring platform, Care, meet safety and performance requirements in Europe. This makes Aura the first product of its kind to receive CE-marking for respiratory infection detection using smart wearable technology.

Aura's algorithm analyzes vital signs from Empatica's smartwatches, comparing data against historical baselines unique to each wearer. Requiring no manual input, when changes in a user's data suggest their body is beginning to fight an infection, Aura automatically displays a warning to Empatica's smartphone-based Care App, as well as to the cloud-based Care Portal, optionally informing their healthcare provider or caregivers. Through the Care Portal, healthcare professionals can simultaneously monitor the risk status of hundreds of individuals remotely, making Aura a powerful tool for maintaining healthy communities and preventing outbreaks.

In validation studies, Aura showed a sensitivity of 0.94 for detecting patients with a possible infection. Detection happened on average two days after viral inoculation. The results apply to general physiological responses that arose from three different viruses: H1N1, Rhinovirus, and SARS-CoV-2. Aura, for use in ages 14 and up, is now available across Europe and the UK for healthcare providers and other professionals seeking to contain the spread of infectious diseases within their communities. Empatica, in the process of gaining FDA-approval for Aura, has partnered with the US Department of Health and Human Services (via the Biomedical Advanced Research and Development Authority) and Stanford University to run a nationwide validation study with US-based healthcare workers.

"Our goal with Aura was to create an effective, scalable, and affordable tool for screening infection risk and supporting testing efficiency, all while monitoring people's health remotely. This result is a win for science and technology against the COVID-19 pandemic. We hope Aura can play an important role in controlling new outbreaks and helping people safely get back to work and to a normal life," said Empatica CEO, Matteo Lai.

Related Links:
Empatica


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Immobilization System
Cranial 4Pi Immobilization
Wound Irrigation Solution
Prontosan®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The study is the first to demonstrate a single nanomaterial platform that combines rapid blood clotting, activation of the body’s own latent growth factors, recruitment of bone-forming stem cells and enhanced bone regeneration. (Image Credit: Stef Zingsheim/University of Sydney)

Nanobone Material Activates Natural Repair Signals to Regrow Bone

Cleft lip and palate is a birth defect that affects about 1 in 700 children and occurs when parts of the upper lip or roof of the mouth do not fully fuse during pregnancy. Repairing the resulting jawbone... Read more

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more

Business

view channel
Image: Sempresto’s Smartphone-Integrated Epinephrine Auto-Injector Wins Red Dot Design Award (Photo courtesy of Sempresto)

Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award

Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.